Merck Poised to Revolutionize Cancer Treatment with Innovative Subcutaneous Keytruda

Merck & Co plans to introduce a subcutaneously administered form of its cancer drug Keytruda in the U.S. The move aims to cut administration time significantly, hoping to see peak adoption within two years. The drug's sales in 2024 are projected at nearly $30 billion.

Merck & Co announced plans to launch a subcutaneous version of its leading cancer drug, Keytruda, in the United States by October 1. This version, pending FDA approval scheduled for September 23, aims to streamline administration by injecting under the skin, shortening treatment time compared to existing intravenous methods.

Joanne Monahan, a senior vice president at Merck, emphasized the prompt availability of the product post-approval, citing sufficient supplies to meet anticipated demand. The company forecasts peak adoption rates of up to 40% among patients currently using Keytruda, particularly in those receiving monotherapy and early-stage cancer treatments.

Keytruda, the top-selling prescription drug with nearly $30 billion in sales for 2024, is integral to Merck's growth strategy. The subcutaneous version is also planned for European markets by 2026. Merck and its partner, Alteogen, are prepared for potential patent disputes yet remain committed to advancing Keytruda's new formulation.

(With inputs from agencies.)